Bemnifosbuvir/Ruzasvir for Drug Interaction Study
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to study how the combination of two drugs, Bemnifosbuvir and Ruzasvir, interacts with either Digoxin or Rosuvastatin, medications commonly used for heart conditions and cholesterol. Participants will help researchers understand any effects these drugs might have on each other when taken together. The trial seeks individuals willing to follow strict study rules, including using two forms of birth control and avoiding other medications. It suits those who are generally healthy, with a minimum weight of 110 pounds and a body mass index (BMI) between 18 and 30. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new combination therapy.
Will I have to stop taking my current medications?
Yes, you will need to stop taking your current prescription and over-the-counter medications to participate in this trial.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that Bemnifosbuvir and Ruzasvir are generally safe when used together. Studies have found that this combination is unlikely to cause problems when taken with other medications. Earlier trials with healthy volunteers demonstrated that participants tolerated these drugs well, without major issues. Animal studies also revealed no major safety concerns. These findings suggest that Bemnifosbuvir and Ruzasvir are likely safe for humans.12345
Why are researchers excited about this trial's treatments?
Researchers are excited about the combination of Bemnifosbuvir and Ruzasvir because these treatments offer a fresh approach to managing drug interactions, particularly with common medications like digoxin and rosuvastatin. Unlike other treatments that may not effectively address the complexities of drug interactions, Bemnifosbuvir and Ruzasvir are being studied for their potential to minimize adverse interactions while maintaining efficacy. This could be a game-changer for patients who rely on multiple medications, as it aims to optimize safety and therapeutic outcomes.
What evidence suggests that this trial's treatments could be effective?
Research has shown that the combination of bemnifosbuvir and ruzasvir effectively treats certain viral infections. One study found that 98% of patients had no detectable virus in their blood 12 weeks after completing treatment, indicating strong efficacy. The combination was also safe in healthy individuals, with no major issues reported. This trial focuses on how bemnifosbuvir and ruzasvir interact with other drugs, such as Digoxin and Rosuvastatin, in different treatment arms. While current research examines these interactions, previous results are promising for treating infections.12346
Are You a Good Fit for This Trial?
This trial is for healthy volunteers who weigh at least 50 kg with a BMI of 18-30. Participants must use two birth control methods from screening until 90 days after the last dose and agree to follow study rules.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single oral dose of Bemnifosbuvir/Ruzasvir and are monitored for drug-drug interactions with Digoxin and Rosuvastatin
Follow-up
Participants are monitored for safety and pharmacokinetics after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Bemnifosbuvir/Ruzasvir
Find a Clinic Near You
Who Is Running the Clinical Trial?
Atea Pharmaceuticals, Inc.
Lead Sponsor